KPTI Stock Summary and Trading Ideas (Karyopharm Therapeutics | NASDAQ:KPTI)

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Karyopharm Therapeutics trades on the NASDAQ stock market under the symbol KPTI.

As of March 26, 2026, KPTI stock price climbed to $5.57 with 3,891,860 million shares trading.

KPTI has a beta of 1.54, meaning it tends to be more sensitive to market movements. KPTI has a correlation of 0.06 to the broad based SPY ETF.

KPTI has a market cap of $109.27 million. This is considered a Micro Cap stock.

Last quarter Karyopharm Therapeutics reported $34 million in Revenue and -$2.23 earnings per share. This beat revenue expectation by $919,000 and missed earnings estimates by -$.13.

In the last 3 years, KPTI traded as high as $73.05 and as low as $3.51.

The top ETF exchange traded funds that KPTI belongs to (by Net Assets): VTI, VXF, IWC, PRFZ.

KPTI has underperformed the market in the last year with a price return of -0.5% while the SPY ETF gained +13.4%. KPTI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.4% and -36.3%, respectively, while the SPY returned -6.3% and -4.4%, respectively.

KPTI support price is $4.80 and resistance is $5.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPTI shares will trade within this expected range on the day.